{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-202551","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.796915+00:00","generated_at":"2026-05-31T08:42:41.008666+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics promotes Arun Swaminathan to CEO effective Nov 1, 2024; Howard Berman becomes Executive Chairman","bullets":["Arun Swaminathan, current CBO, promoted to CEO effective Nov 1, 2024; succeeds Howard Berman.","Howard Berman resigns as CEO effective Oct 31, 2024, remains as Executive Chairman and director.","Swaminathan appointed to Board of Directors as Class III director effective immediately.","Swaminathan led Dr. Reddy's licensing transaction worth up to $700M; executed over $6B in deals.","Company expects upcoming Alzheimer's data at CTAD24 on Oct 29, 2024; continues progress on COYA 302 in ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-202551","json":"https://secwatch.observer/filing/0001193125-24-202551.json","markdown":"https://secwatch.observer/filing/0001193125-24-202551.md","text":"https://secwatch.observer/filing/0001193125-24-202551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/d861081d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:42:41.008666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c25afc83b","claim":"Howard Berman resigned as Chief Executive Officer at Coya Therapeutics, Inc..","evidence_excerpt":"Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"88bac2edb1","claim":"Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..","evidence_excerpt":"Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8cfe6b9117","claim":"Arun Swaminathan was appointed as Director at Coya Therapeutics, Inc..","evidence_excerpt":"Dr. Swaminathan was also appointed to the Company’s Board as a Class III director to serve until the Company’s 2025 annual meeting of stockholders","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9fe45df220","claim":"Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..","evidence_excerpt":"After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}